Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. reports news on the commercialization and development of photodynamic therapy in dermatology. The company’s core product platform includes Ameluz, an aminolevulinic acid hydrochloride topical gel used with the RhodoLED red-light lamp series, with an established focus on actinic keratoses and clinical programs addressing additional dermatologic conditions.
Recurring updates include financial results, U.S. commercial performance, clinical data for Ameluz PDT, FDA-related label-expansion activity, patent proceedings, and business updates tied to the company’s U.S. product rights, regulatory approvals, intellectual property, and manufacturing rights.
Biofrontera Inc. (Nasdaq: BFRI) announced its initial public offering (IPO) of 3,600,000 units, each priced at $5.00, consisting of one share of common stock and one warrant. The offering could generate $18 million in gross proceeds, before deducting fees. A 30-day option allows underwriters to purchase an additional 540,000 shares. Trading for these securities is set to start on October 29, 2021, with the offering closing expected on November 2, 2021.